Table 2.

Summary table including responder analysis and adverse event data after one single BTA treatment of SPG.

			Efficacy outcome (attack frequency per week)
	Intervention			Reduction in attack frequency from BL (%)						Adverse event
Patient number	Approach	BTA (IU)	BL	M1	M2	M3	M4	M5	M6	Resolved <4 weeks	On-going >4 weeks
1	Transnasal	25	30.2	−57%	−3%	−32%	−53%	−28%	−12%	Accommodation problems
2	Transnasal	25	15.0	−57%	−67%	−65%	−82%	−92%	−93%	None
3	Transnasal	25	15.2	−97%	−97%	−85%	−20%	+5%	−3%	Accommodation problems
4	Transnasal	25	17.5	−97%	−99%	−100%	−100%	−100%	−97%	None
5	Transnasal	25	3.5	+43%	+21%	+42%	+22%	+57%	+36%	Temporal headache, misplaced injection
6	Transnasal	50	4.5	−78%	−61%	−56%	−78%	−61%	−67%	Anterior epistaxis
7	Lateral	50	14.3	−23%	−18%	−35%	−18%	−38%	−25%	None
8	Transnasal	50	15.4	−14%	NA	NA	NA	NA	NA	Anterior epistaxis, accommodation and jaw problems	CH attack- related weakness in one foot
9	Transnasal	50	NA	NA	NA	NA	NA	NA	NA	Anterior epistaxis
10	Transnasal	50	42.6	−21%	NA	NA	NA	NA	NA	Posterior epistaxis

^≥50% improvement from baseline, depicted in bold.

BTA: onabotulinumtoxinA; SPG: sphenopalatine ganglion; CH: cluster headache; M: month; NA: not available; BL: baseline.